National Institutes of Health: Peritoneal Neoplasms trials

The registry lists 29 Peritoneal Neoplasms studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 15 have results posted.

Early Phase 1 1Phase 1 8Phase 2 18Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingNCT04847063Phase 1
• Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisCompletedNCT05185947Phase 2Results posted
• Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal CarcinomatosisTerminatedNCT04034251Phase 2Results posted
• Surgery and Heated Chemotherapy for Adrenocortical CarcinomaCompletedNCT01833832Phase 2Results posted
• Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal CancerTerminatedNCT01681368Phase 2Results posted
• Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal CancerCompletedNCT01313078Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT00445549Phase 2Results posted
• VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00436501Phase 1/2Results posted
• Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal CancerCompletedNCT00436215Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00388037Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3Results posted
• Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity CancerCompletedNCT00093496Phase 2Results posted
• Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00083122Phase 2Results posted
• Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal CarcinomatosisCompletedNCT00052962Phase 3Results posted
• Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and ChemotherapyCompletedNCT00004547Phase 2Results posted
• Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02042430Early Phase 1
• Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerCompletedNCT01264432Phase 1
• Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal MetastasesWithdrawnNCT01095523Phase 2
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 1
• AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00348699Phase 1
• Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity CancerCompletedNCT00132067Phase 2
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
• Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity CancerTerminatedNCT00091195Phase 2
• Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube CancersCompletedNCT00086567
• Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00026091Phase 2
• SU5416 and Carboplatin to Treat Ovarian CancerCompletedNCT00006155Phase 1
• Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal CarcinomatosisCompletedNCT00001569Phase 1
• Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal CarcinomatosisCompletedNCT00001332Phase 1